Factor Consistency of Neuropsychological Test Battery Versions in the NACC Uniform Data Set.

Factor Consistency of Neuropsychological Test Battery Versions in the NACC Uniform Data Set. Alzheimer Dis Assoc Disord. 2020 Mar 24;: Authors: Culhane JE, Chan KCG, Teylan MA, Chen YC, Mock C, Gauthreaux K, Kukull WA Abstract The proprietary neuropsychological tests (Form C1) of the National Alzheimer's Coordinating Center (NACC) Uniform Data Set were replaced with nonproprietary versions (Form C2) chosen to closely model their proprietary counterparts. Correlations between analogous test pairs as measured in previous work were good (0.68-0.78), but it is unclear whether the paired tests represent the same set of common factors of cognition or if important factors specific to C1 or C2 only exist. The authors performed multiple factor analysis to analyze correlated C1 and C2 data. They included participants who completed both neuropsychological batteries within 1 year with no change in cognitive status. They found that the C1 and C2 neuropsychological test pairs are strongly related and are represented by the same principal factors. These findings support the use of the C2 test results in conjunction with C1 in longitudinal analyses of NACC data. PMID: 32218065 [PubMed - as supplied by publisher]
Source: Alzheimer Disease and Associated Disorders - Category: Psychiatry Tags: Alzheimer Dis Assoc Disord Source Type: research

Related Links:

Abstract Alzheimer's disease (AD) was first described and diagnosed by Dr. Alois Alzheimer in 1906 (Hippius and Neundorfer, Dialogues Clin Neurosc 5:101-108, 2003). According to World Health Organization (WHO), AD is the most common cause of dementia, accounting for as many as 60-70% of senile dementia cases and affecting 47.5 million people worldwide (data from 2015) (Dementia Fact Sheet No 362. http://who.int/mediacentre/factsheets/fs362/en/ ). The median survival time after the onset of dementia ranges from 3.3 to 11.7 years (Todd et al. Int J Geriatr Psychiatry 28:1109-1124, 2013). AD is characterized as ...
Source: Clin Med Res - Category: Research Authors: Tags: Adv Exp Med Biol Source Type: research
This study was carried out on the principles of molecular docking, chemical synthesis, and enzymatic inhibition of BACE1 enzymes via biaryl guanidine-based ligands. Based on virtual screening, thirteen different compounds were synthesized and subsequently evaluated via in vitro and in vivo studies. Among them, 1,3-bis(5,6-difluoropyridin-3-yl)guanidine (compound (9)) was found the most potent (IC50 = 97 ± 0.91 nM) and active to arrest (99%) β-secretase enzymes (FRET assay). Furthermore, it was found to improve the novel object recognition test and Morris water maze test significantly (p
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Authors: Wang Y, Chen F, Wang P, Mana L, Sheng N, Huang S Abstract Shenzhiling oral liquid (SZL) is a Traditional Chinese Medicine (TCM) compound to be approved by the China Food and Drug Administration (CFDA) (Z20120010) for the treatment of mild-to-moderate Alzheimer's disease (AD). However, its mechanism in early AD is not clear. We studied its mechanism in protecting myelin. Three-month-old APPswe/PS1dE9double transgenic mice were used as AD model and wild-type C57BL/6 mice were used as control. After 3-month intervention, the Morris water maze was used to detect behavioural changes. Myelin mTOR pathway (PI3K, ...
Source: International Journal of Immunopathology and Pharmacology - Category: Allergy & Immunology Tags: Int J Immunopathol Pharmacol Source Type: research
Authors: van Dyck CH, Arnsten AFT, Padala PR, Brawman-Mintzer O, Lerner AJ, Porsteinsson AP, Scherer RW, Levey AI, Herrmann N, Jamil N, Mintzer JE, Lanctôt KL, Rosenberg PB Abstract The public health burden of Alzheimer's disease (AD) is related not only to cognitive symptoms, but also to neuropsychiatric symptoms, including apathy. Apathy is defined as a quantitative reduction of goal-directed activity in comparison to a previous level of functioning and affects 30%-70% of persons with AD. Previous attempts to treat apathy in AD-both nonpharmacologically and pharmacologically-have been wanting. Catecholamine...
Source: The American Journal of Geriatric Psychiatry - Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research
AbstractChanges in neurovascular coupling are associated with both Alzheimer ’s disease and vascular dementia in later life, but this may be confounded by cerebrovascular risk. We hypothesized that hemodynamic latency would be associated with reduced cognitive functioning across the lifespan, holding constant demographic and cerebrovascular risk. In 387 adults aged 18–85 (mean = 48.82), dynamic causal modeling was used to estimate the hemodynamic response function in the left and right V1 and V3-ventral regions of the visual cortex in response to a simple checkerboard block design stimulus with mi...
Source: Anatomy and Embryology - Category: Anatomy Source Type: research
In this study, five new evaluators reviewed each other’s readings of the scans, and the researchers rated how well the evaluators agreed with one another’s assessments. Perfect agreement was scored as 1, and no agreement was scored as 0. Agreement was 0.87 across all 241 patients.The most common side effects were headache, pain at the injection site, and increased blood pressure, with all side effects occurring in less than 1.5% of the patients.Flortaucipir F18 was developed by Avid Radiopharmaceuticals Inc., a subsidiary of Eli Lilly and Co. In astatement, Lilly noted that availability of flortaucipir F18 will...
Source: Psychiatr News - Category: Psychiatry Tags: Alzheimer's disease Avid Radiopharmaceuticals cognitive impairment diagnostic Food and Drug Administration imaging protein tau tau neurofibrillary tangles Source Type: research
Publication date: Available online 29 May 2020Source: Pharmacology Biochemistry and BehaviorAuthor(s): Noura El Adle Khalaf, Farida Mohamed El Banna, Mona Younis Youssef, Youssef Mohammed Mosaad, Mohamed-Hesham Yousry Daba, Rehab Hamdy Ashour
Source: Pharmacology Biochemistry and Behavior - Category: Biochemistry Source Type: research
Condition:   Agitation in Patients With Dementia of the Alzheimer's Type Interventions:   Drug: AVP-786;   Drug: Placebo Sponsor:   Avanir Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Flortaucipir F18 (Tauvid) for use with PET imaging helps estimate the density and distribution of tau pathology in adults with cognitive impairment who are being evaluated for Alzheimer ’ s disease.FDA Approvals
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Psychiatry News Alert Source Type: news
Days before she tested positive for COVID-19 in early April, Tanya Beckford was already worried about dying because of the conditions in the Connecticut nursing home where she has worked for 23 years. She wasn’t feeling well and says she and her co-workers, facing a shortage of masks, gloves and gowns, had started wearing plastic trash bags over their uniforms for protection as they cared for infected residents. Beckford, a certified nursing assistant (CNA) in the Alzheimer’s unit at Newington Rapid Recovery Rehab Center in Newington, Connecticut, had been running a low-grade fever but says the facility was on...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Alzheimer's | Brain | Neurology | Psychiatry